FindTrial
Sign In

Analyzing the effectiveness of vaginal misoprostol tablet in ease of performing hysteroscopy and prevention of the adverse events while performing hysteroscopy

Evaluation of Vaginal Misoprostol as Cervical Priming Agent in Patients Undergoing Hysteroscopy: A Randomized Double-Blind Placebo-Controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/09/057503
Enrollment
36
Registered
2023-09-12
Start date
Unknown
Completion date
Unknown
Last updated
2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N920- Excessive and frequent menstruation with regular cycle Health Condition 2: N979- Female infertility, unspecified

Interventions

Intervention1: Misoprostol group: Patients will recieve vaginal misoprostol 400 mcg 4 hours prio r to the hysteroscopy Control Intervention1: Placebo group: Patients will recieve the vaginal betadine

Sponsors

Dr Chandramma Dayananda Sagar institute of Medical Education and Research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All women undergoing diagnostic and operative hysteroscopy

Exclusion criteria

Exclusion criteria: Refusal for consent, suspected genital malignancy, uncontrolled bleeding per vaginum, active genital infection, allergic to misoprostol & betadine, previous cervical surgeries, mullerian anomalies of the uterus

Design outcomes

Primary

MeasureTime frame
Cervical passage time, need for cervical dilatationTimepoint: 6 months from the date of approval—

Secondary

MeasureTime frame
complications during cervical entry, misoprostol related side-effectsTimepoint: 6 months from the date of approval—

Countries

India

Contacts

Public ContactNithin M

CDSIMER, unit of DSU

pranathiaravind@gmail.com9900634112

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026